000			02995cam a2200349 a 4500
003			EG-GiCUC
005			20250223032109.0
008			181101s2018 ua h f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.24.M.Sc.2018.No.E
100	0		_aNooran Mohammed Abdelhameed
245	1	0	_aEffect of intravitreal injection of anti-VEGF in traction associated diabetic macular edema / _cNooran Mohammed Abdelhameed ; Supervised Khaled Essmat Alrakhawy , Mohamed Hosny Elbradey , Ahmed Abdelsattar Dahab
246	1	5	_aتأثير الحقن فى الجسم الزجاجى للعوامل المضادة للنسيج المبطن لجدار الأوعية الدموية فى حالات الارتشاح السكرى لماقولة العين المصحوبة بالشد
260			_aCairo : _bNooran Mohammed Abdelhameed , _c2018
300			_a67 P. : _bfacsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Ophthalmology
520			_aObjective: To study the effect of intravitreal anti-VEGF injection in traction associated diabetic macular edema regarding central macular thickness (CMT) and best corrected visual acuity (BCVA). Study design: A prospective clinical trial. Methods: 30 eyes of diabetic pateints with center involved macular edema associated with Epiretinal membrane (ERM) causing traction as detected by OCT ± biomicroscopy, received atleast 3 consecutive intravitreal injection of anti-VEGF, CMT and BCVA was measured at baseline and after 3 injections by OCT and snellen chart respectively ,iclusion criteria included naïve eyes as regarding macular treatment with CMT 270æm or more,exclusion criteria included any previous intravitreal injections or macular laser, ischemic maculopathy,dense cataract ,glaucoma any systemic contraindication for intravitreal anti-VEGF. The CMT and BCVA of the 30 eyes was used for statistical analysis to detect if there is any improvement post injections. Results: The mean baseline BCVA was 0.16±0.10 decimal units and the mean final BCVA was 0.31±0.20 decimal units, the mean baseline CMT was 477±141 æm and the final CMT was 362±97æm. After 3 IVI the final CMT and BCVA were significantly lower than baseline (P<0.001). Conclusion: Intravitreal injection of anti-VEGF is not contraindicated in traction associated diabetic macular edema. Statistically significant improvement in both CMT and BCVA occurred after 3 consecutive anti-VEGF injection in these cases. P<0.001
530			_aIssued also as CD
653		4	_aAnti-VEGF
653		4	_aIntravitreal injection
653		4	_aTraction
700	0		_aAhmed Abdelsattar Dahab , _eSupervisor
700	0		_aKhaled Essmat Alrakhawy , _eSupervisor
700	0		_aMohamed Hosny Elbradey , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c68281 _d68281